Showing results (51-60 of 88) with videos related to

Sort By:
Pageof 9
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 7, 2017
Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimatesMaria Sepúlveda, Marta Aldea, Domingo Escudero, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|September 30, 2016
Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosisNathaniel Lizak, Alessandra Lugaresi, Raed Alroughani, et al.
Brain : a Journal of Neurology|September 12, 2015
Defining reliable disability outcomes in multiple sclerosisTomas Kalincik, Gary Cutter, Tim Spelman, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 28, 2025
Corticosteroid treatment of multiple sclerosis relapses is associated with lower disability worsening over 5 yearsJodie I Roberts, Sifat Sharmin, Dana Horakova, et al.
Neurology|October 7, 2020
Treatment Response Score to Glatiramer Acetate or Interferon Beta-1aFrancesca Bovis, Tomas Kalincik, Fred Lublin, et al.
Brain : a Journal of Neurology|May 10, 2020
Early clinical markers of aggressive multiple sclerosisCharles B Malpas, Ali Manouchehrinia, Sifat Sharmin, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|December 6, 2024
Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data NetworkJohannes Lorscheider, Alessio Signori, Suvitha Subramaniam, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 7, 2017
Long-term disability trajectories in primary progressive MS patients: A latent class growth analysisAlessio Signori, Guillermo Izquierdo, Alessandra Lugaresi, et al.
Computer Methods and Programs in Biomedicine|June 19, 2021
Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progressionEdward De Brouwer, Thijs Becker, Yves Moreau, et al.
Pageof 9